These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 33477154)

  • 21. Comparative efficacy of metformin combined with cabergoline versus metformin alone in patients with PCOS and hyperprolactinemia: A systematic review and meta-analysis of randomized controlled trials.
    Nizamani M; Zaheer Uddin M; Nagdev C; Ahmed N; Raza A
    Eur J Obstet Gynecol Reprod Biol; 2024 Aug; 299():289-295. PubMed ID: 38945085
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Beneficial Effects of High Doses of Cabergoline in the Treatment of Giant Prolactinoma Resistant to Dopamine Agonists: A Case Report with a 21-Year Follow-Up.
    de Castro LF; Magalhães Gonzaga MF; Naves LA; Luiz Mendonça J; Oton de Lima B; Casulari LA
    Horm Res Paediatr; 2018; 89(1):63-70. PubMed ID: 28954263
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors of dopamine agonist resistance in prolactinoma patients.
    Vermeulen E; D'Haens J; Stadnik T; Unuane D; Barbe K; Van Velthoven V; Gläsker S
    BMC Endocr Disord; 2020 May; 20(1):68. PubMed ID: 32429916
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized pilot study of cabergoline, a dopamine receptor agonist: effects on body weight and glucose tolerance in obese adults.
    Gibson CD; Karmally W; McMahon DJ; Wardlaw SL; Korner J
    Diabetes Obes Metab; 2012 Apr; 14(4):335-40. PubMed ID: 22074059
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia.
    Vroonen L; Lancellotti P; Garcia MT; Dulgheru R; Rubio-Almanza M; Maiga I; Magne J; Petrossians P; Auriemma R; Daly AF; Beckers A
    Endocrine; 2017 Jan; 55(1):239-245. PubMed ID: 27709470
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prolactin excess: treatment and toxicity.
    Gillam MP; Fideleff H; Boquete HR; Molitch ME
    Pediatr Endocrinol Rev; 2004 Nov; 2 Suppl 1():108-14. PubMed ID: 16456489
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of Pituitary Surgery and High-Dose Cabergoline Therapy on Metabolic Profile in Patients With Prolactinoma Resistant to Conventional Cabergoline Treatment.
    Pirchio R; Auriemma RS; Solari D; Arnesi M; Pivonello C; Negri M; de Angelis C; Cavallo LM; Cappabianca P; Colao A; Pivonello R
    Front Endocrinol (Lausanne); 2021; 12():769744. PubMed ID: 34917030
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radiographic and Hormonal Regression in Prolactinomas: An Analysis of Treatment Failure.
    Akinduro OO; Lu VM; Izzo A; De Biase G; Vilanilam G; Van Gompel JJ; Bernet V; Donaldson A; Olomu O; Meyer FB; Quinones-Hinojosa A; Chaichana KL
    World Neurosurg; 2019 Sep; 129():e686-e694. PubMed ID: 31181361
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
    Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
    Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hyperprolactinemia: pathophysiology and management.
    Verhelst J; Abs R
    Treat Endocrinol; 2003; 2(1):23-32. PubMed ID: 15871552
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of Pituitary and Other Tumours with Cabergoline: New Mechanisms and Potential Broader Applications.
    Lin S; Zhang A; Zhang X; Wu ZB
    Neuroendocrinology; 2020; 110(6):477-488. PubMed ID: 31597135
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?
    Dogansen SC; Selcukbiricik OS; Tanrikulu S; Yarman S
    Pituitary; 2016 Jun; 19(3):303-10. PubMed ID: 26830552
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prolactinomas Resistant to Dopamine Agonists: Pathophysiology and Treatment.
    Shimon I
    Arch Med Res; 2023 Dec; 54(8):102883. PubMed ID: 37689507
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.
    Colao A; Di Sarno A; Cappabianca P; Di Somma C; Pivonello R; Lombardi G
    N Engl J Med; 2003 Nov; 349(21):2023-33. PubMed ID: 14627787
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Falsely low serum prolactin in two cases of invasive macroprolactinoma.
    Schöfl C; Schöfl-Siegert B; Karstens JH; Bremer M; Lenarz T; Cuarezma JS; Samii M; von zur Mühlen A; Brabant G
    Pituitary; 2002; 5(4):261-5. PubMed ID: 14558675
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Update on prolactinomas. Part 2: Treatment and management strategies.
    Wong A; Eloy JA; Couldwell WT; Liu JK
    J Clin Neurosci; 2015 Oct; 22(10):1568-74. PubMed ID: 26243714
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Hyperprolactinemia in the postmenopause: versions and contraversions].
    Leshchenko OY
    Ter Arkh; 2021 Oct; 93(10):1234-1239. PubMed ID: 36286827
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Giant prolactinoma and effectiveness of medical management.
    Acharya SV; Gopal RA; Menon PS; Bandgar TR; Shah NS
    Endocr Pract; 2010; 16(1):42-6. PubMed ID: 19703803
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alternative Treatment Strategies in Women Poorly Tolerating Moderate Doses of Bromocriptine.
    Krysiak R; Szkróbka W; Okopień B
    Exp Clin Endocrinol Diabetes; 2017 Jun; 125(6):360-364. PubMed ID: 28073129
    [No Abstract]   [Full Text] [Related]  

  • 40. Management of prolactinomas: a survey of physicians from the Middle East and North Africa.
    Beshyah SA; Sherif IH; Chentli F; Hamrahian A; Khalil AB; Raef H; El-Fikki M; Jambart S
    Pituitary; 2017 Apr; 20(2):231-240. PubMed ID: 27783196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.